Amphastar Pharmaceuticals, Inc.
- AMPH · Nasdaq
- Pharmaceutical Preparations
- Rancho Cucamonga, CA
- 1,976 employees
- CIK 0001297184
Updated from SEC filings through
Top things to know
Executives
- Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER 4, 2026-03-17
- William J. Peters CFO, EVP & TREASURER 4, 2026-09-23
- Mary Z. Luo COO, Chief Scientist, Chairman 4, 2026-03-17
- Jacob Liawatidewi Executive Vice President of Sales and Marketing 10-K, 2026-02-26
- Rong Zhou SENIOR EVP, PRODUCTION CENTER 4, 2026-09-17
- Yakob Liawatidewi EVP CORP ADMIN CENTER 4, 2026-03-17
Amphastar Pharmaceuticals, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Rancho Cucamonga, CA. It trades as AMPH on Nasdaq. Revenue was $720M in the fiscal year ending December 31, 2025, -1.7% from the year before. It reported about 1,976 employees. Jack Y. Zhang is CEO & CHIEF SCIENTIFIC OFFICER.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $720M 10-K, 2026-02-26 | $732M 10-K, 2026-02-26 | $644M 10-K, 2026-02-26 | $499M 10-K, 2025-03-03 | $438M 10-K, 2024-02-29 |
| Operating income | $140M 10-K, 2026-02-26 | $205M 10-K, 2026-02-26 | $197M 10-K, 2026-02-26 | $107M 10-K, 2025-03-03 | $69.9M 10-K, 2024-02-29 |
| SG&A | $130M 10-K, 2026-02-26 | $94.5M 10-K, 2026-02-26 | $80.4M 10-K, 2026-02-26 | $66.6M 10-K, 2025-03-03 | $68.9M 10-K, 2024-02-29 |
| Net income | $98.1M 10-K, 2026-02-26 | $160M 10-K, 2026-02-26 | $138M 10-K, 2026-02-26 | $91.4M 10-K, 2025-03-03 | $62.1M 10-K, 2024-02-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jack Yongfeng Zhang | Board member (per proxy) bio: Chief Executive Officer, President, Chief Scientific Officer and Director | DEF 14A, 2026-04-13 |
| Jack Y. Zhang | CEO & CHIEF SCIENTIFIC OFFICER | 4, 2026-03-17 |
| William J. Peters | CFO, EVP & TREASURER | 4, 2026-09-23 |
| Mary Ziping Luo | Board member (per proxy) bio: Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors | DEF 14A, 2026-04-13 |
| Mary Z. Luo | COO, Chief Scientist, Chairman | 4, 2026-03-17 |
| Jacob Liawatidewi Executive VP Corporate Administration Center at Amphastar Pharmaceuticals, Inc. | Executive Vice President of Sales and Marketing | 10-K, 2026-02-26 |
| Rong Zhou | SENIOR EVP, PRODUCTION CENTER | 4, 2026-09-17 |
| Yakob Liawatidewi | EVP CORP ADMIN CENTER | 4, 2026-03-17 |
| Anthony Pierce | Class III director | 8-K, 2026-07-13 |
| Floyd F. Petersen | Board member (per proxy) bio: Director | DEF 14A, 2026-04-13 |
| Gayle Deflin | Board member (per proxy) bio: Director | DEF 14A, 2026-04-13 |
| David Gaugh | Director | 10-K, 2026-02-26 |
| Diane G. Gerst | Director | 10-K, 2026-02-26 |
| Floyd Petersen | Director | 10-K, 2026-02-26 |
| Gayle M. Deflin | Director | 10-K, 2026-02-26 |
| Howard Lee | Director | 10-K, 2026-02-26 |
What Amphastar Pharmaceuticals, Inc. does
We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST ® .
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 42.7 million (as of October 30, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $633M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting June 1, 2026 (filed April 13, 2026) | DEF 14A, April 13, 2026 |
| Auditor | Ernst & Young LLP (Irvine, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 5, 2026 | William J. Peters CFO, EVP & TREASURER | Sale | 28,631 | $815K | Form 4, November 6, 2026 |
| September 21, 2026 | William J. Peters CFO, EVP & TREASURER | Sale | 4,139 | $103K | Form 4, September 23, 2026 |
| September 16, 2026 | Rong Zhou SENIOR EVP, PRODUCTION CENTER | Sale | 10,000 | $239K | Form 4, September 17, 2026 |
| September 2, 2026 | Rong Zhou SENIOR EVP, PRODUCTION CENTER | Sale | 3,187 | $75K | Form 4, September 3, 2026 |
| August 11, 2026 | Richard K. Prins Director | Sale | 7,973 | $162K | Form 4, August 12, 2026 |
| August 7, 2026 | William J. Peters CFO, EVP & TREASURER | Sale | 8,180 | $184K | Form 4, August 11, 2026 |
| December 17, 2025 | Rong Zhou SENIOR EVP, PRODUCTION CENTER | Sale | 9,787 | $256K | Form 4, December 18, 2025 |
| December 12, 2025 | Floyd F. Petersen Director | Sale | 4,163 | $108K | Form 4, December 15, 2025 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-08
- Item 8.01 Other events
- 8-K filed 2026-06-03
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-16
- Item 8.01 Other events
- 8-K filed 2026-03-06
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-06
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Amphastar Pharmaceuticals, Inc.
- What does Amphastar Pharmaceuticals, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST ® ."
- What is Amphastar Pharmaceuticals, Inc.'s revenue?
- $720M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Amphastar Pharmaceuticals, Inc. profitable?
- Amphastar Pharmaceuticals, Inc. reported net income of $98.1M for the fiscal year ending December 31, 2025.
- How many employees does Amphastar Pharmaceuticals, Inc. have?
- About 1,976 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Amphastar Pharmaceuticals, Inc.?
- Jack Y. Zhang, CEO & CHIEF SCIENTIFIC OFFICER, as named in a 4 filed March 17, 2026.
- Who is the CFO of Amphastar Pharmaceuticals, Inc.?
- William J. Peters, CFO, EVP & TREASURER, as named in a 4 filed September 23, 2026.
- Where is Amphastar Pharmaceuticals, Inc. headquartered?
- Rancho Cucamonga, CA.
- What is Amphastar Pharmaceuticals, Inc.'s stock ticker?
- AMPH on Nasdaq.
- What industry is Amphastar Pharmaceuticals, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Amphastar Pharmaceuticals, Inc.'s website?
- amphastar.com.
- When does Amphastar Pharmaceuticals, Inc. report earnings next?
- February 4, 2027. Source: estimate_8k_pattern.
- Is Amphastar Pharmaceuticals, Inc. a public company?
- Yes. Amphastar Pharmaceuticals, Inc. files with the SEC under CIK 0001297184 and trades as AMPH.
- Who audits Amphastar Pharmaceuticals, Inc.?
- Ernst & Young LLP, Irvine, California, as named in its latest annual report (10-K).
- How many shares of Amphastar Pharmaceuticals, Inc. are outstanding?
- 42.7 million shares as of October 30, 2026, from its 10-Q filed November 5, 2026.
- What is Amphastar Pharmaceuticals, Inc.'s public float?
- $633M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Amphastar Pharmaceuticals, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is Amphastar Pharmaceuticals, Inc.'s annual shareholder meeting?
- June 1, 2026, per its proxy statement (DEF 14A) filed April 13, 2026.
- Have Amphastar Pharmaceuticals, Inc. insiders traded stock recently?
- Since July 2, 2025, officers and directors reported 15 open-market sales worth about $2.6M and 0 purchases on Forms 4 and 5. The most recent: William J. Peters (CFO, EVP & TREASURER) sold 28,631 shares on November 5, 2026.